Finding · criterion S5
The criterion the licensed services fail and the research vendors pass
13 of the 15 checked research vendors publish a reachable analytical document for what they sell. 1 of the 30 checked telehealth services does. The sellers operating outside the prescription system publish more laboratory evidence about the substance in the vial than the licensed services do.
Criterion S5, analytical documentation asks for a document a reader can open: a certificate of analysis, a chromatogram, or a lot report, at a URL. The words lab-tested, third-party tested or rigorously tested satisfy nothing, because none of them is a document. That is the whole criterion, and it produces a result that runs against what the market implies.
The number, with both denominators
Across all 47 records, 14 pass S5, 31 fail it, and 2 carry a null. The nulls are excluded from every numerator and named here rather than counted: Peptide Sciences, Science.bio. Against the adjusted denominator of 45 checked records, the count is 14.
Split by kind, the two groups barely overlap. Among the 17 research vendors, 13 publish a document, 2 do not, and 2 carry a null, giving 13 of 15 checked. Among the 30 telehealth services, 1 publishes one, 29 do not, and 0 carry a null, giving 1 of 30 checked. The telehealth records that pass are Ro.
Both denominators matter here more than anywhere else on the site. This piece was withheld for a long time precisely because the telehealth column was mostly nulls, and a rate quoted against a field nobody had checked would have been a fabrication with a percentage sign on it. Every one of the 30 telehealth records has now been checked on this criterion, so the telehealth figure carries no adjusted denominator at all: it is 1 of 30, whole. The remaining 2 nulls belong to the vendor side and are named above.
Why the field splits this way
The explanation is structural, and it is not that one group is more careful than the other. A research vendor sells the compound itself. Purity is the product, the buyer is told to be a laboratory, and a certificate is the ordinary commercial document of that trade, as a spec sheet is for a component supplier. A telehealth service sells a prescription and a fulfillment arrangement. The compounding happens at a pharmacy, the pharmacy holds the batch records, and the service is frequently not the entity that could publish them.
That last clause is where this criterion meets S3, pharmacy identification. A service that does not name the pharmacy filling the order is not in a position to point a reader at that pharmacy's testing either. The two absences travel together, and neither is evidence that any particular vial was untested. What they establish is narrower and checkable: on those records, a reader has no document to open.
What this does not say
It does not say that research vendors are safer. They fail S1 and S3 almost uniformly, they sell to buyers with no clinician between them and the vial, and several of them have received enforcement correspondence recorded elsewhere in this ledger. A certificate is a document about one lot as submitted to one laboratory on one date. It is not an approval, it is not a safety finding, and it says nothing about the vial that ships.
Nor does it say the telehealth services are careless. A pharmacy that never publishes a certificate may test every batch, and several of the failing records assert exactly that. The criterion does not measure testing. It measures whether a reader can see a document, and the honest way to state the result is that on 29 of the 30 checked telehealth records the answer is no.
The reason to publish the number at all is that it runs against what the market implies. The licensed, prescriber-gated, address-publishing side of this field is the side that shows a reader the least laboratory evidence, and a Standard that only produced flattering results for the regulated sellers would not be worth citing.
What the passing documents actually are
The 14 passing records cite 14 documents, and they are not equivalent. Each basis records the laboratory, the figure and the method where the document states them, and the caveats where it does not.
Reading them side by side is the point. Some name an independent laboratory, a lot number, a method and a date. Others are older than the product line they cover, or sit on the seller's own letterhead, or cover a compound other than the one a reader came for. All of them pass S5, because S5 asks whether a document is reachable and not whether it is persuasive. Judging the document is the reader's step, and this list exists so that step is possible.
The full roster
Every record in the ledger with its S5 disposition and the basis recorded against it, including every null, so the counts above can be repeated from this page.
| Seller | Kind | S5 | What was found, or not found |
|---|---|---|---|
| altRx | Telehealth | FAIL | Eight pages were read, covering home, about, contact, terms, privacy and the frequently asked questions, and none publishes a certificate of analysis, a lot number or a testing claim. |
| Behemoth Labz | Research vendor | FAIL | The homepage promises certificates of analysis in general terms, and no certificate, chromatogram or lot report is reachable from any captured page. |
| Biotech Peptides | Research vendor | PASS | A per-lot certificate of analysis is published as a reachable document, reporting 99.94 percent purity by HPLC-UV-MS from MZ Biolabs. |
| Blue Sky Peptide | Research vendor | PASS | A public certificate from MZ Biolabs of Tucson reports 99.97 percent purity on semaglutide lot 1SWS0126 by HPLC-UV-MS, reachable with no login. |
| Care Bare Rx | Telehealth | FAIL | Five pages were read, covering home, questions, about, the weight-loss product page and the terms, and none publishes a certificate, a lot number or any testing claim. |
| Chemyo | Research vendor | PASS | A public laboratory report from Nutri Analytical Testing Laboratories of Anaheim gives 100.00 percent purity on MK-677 lot BA2200 by UHPLC against a claim above 99 percent, reachable with no login. |
| Core Peptides | Research vendor | PASS | Per-lot certificates of analysis published as documents on product pages. |
| CoreAge Rx | Telehealth | FAIL | Five pages were read, covering home, questions, about, privacy and the compounded-semaglutide safety page, and none publishes a certificate, a lot number or any testing claim. |
| Direct Meds | Telehealth | FAIL | The how-it-works and semaglutide pages state that medications undergo third-party testing for purity, safety and potency, and no certificate, lot number or laboratory is named or reachable. |
| Eden | Telehealth | FAIL | No certificate, lot report or test document appears on the treatment pages, the safety page, or among the 1,027 addresses the sitemap lists. |
| Fella Health | Telehealth | FAIL | No certificate of analysis, chromatogram or lot document is linked on any page read, and the treatments page asserts quality without naming a laboratory, a figure or a method. |
| Form Health | Telehealth | FAIL | Eleven pages were searched for thirteen certificate and testing terms, and none returns a certificate, a lot number or a purity figure. |
| Found | Telehealth | FAIL | A comparison table states that medication is independently tested for potency, purity and sterility, and no report is reachable. |
| Gala Health | Telehealth | FAIL | Four pages were read, covering home, about, the compounded GLP-1 page and the terms, and none publishes a certificate, a lot number or any testing claim. |
| He & She MD | Telehealth | FAIL | Sterile compound batches are said to undergo third-party testing, and no test report is reachable on the pages read. |
| HealthRX | Telehealth | FAIL | Medication is described as lot-tracked from the compounding bench to the door, and no lot document is reachable. |
| Henry Meds | Telehealth | FAIL | No certificate, lot report or test document appears on the treatment pages, the FAQ, the terms, or among the 34 addresses the sitemap lists. |
| Hims & Hers | Telehealth | FAIL | No certificate, lot report or test document appears on the compounded product page, in the terms, or among the 2,434 addresses the sitemap lists. |
| Ivim Health | Telehealth | FAIL | No certificate, lot report or test document appears on the safety pages, the pricing page, or among the 466 addresses the sitemap index lists. |
| Leanmeds | Telehealth | FAIL | Eight pages were read, covering home, about, contact, terms, privacy and the frequently asked questions, and none publishes a certificate of analysis, a lot number or a testing claim. |
| LifeMD | Telehealth | FAIL | No certificate, lot report or test document appears on the weight management page, the FAQ, the terms, or among the 1,369 addresses the sitemap lists. |
| Limitless Life Nootropics | Research vendor | PASS | Purity, endotoxin and sterility certificates are published per lot as reachable documents, reporting 99.817 percent purity from TrustPointe Analytics LLC. |
| Loti Labs | Research vendor | PASS | A dated per-lot certificate of analysis for BPC-157 reports 99.9 percent purity by reversed-phase HPLC from Bioviridian Inc, reachable as a public file with no login. |
| MangoRx | Telehealth | FAIL | No certificate, lot report or test document appears on the product page, the FAQ, the pharmacy disclaimer, or in the sitemap. |
| Mochi Health | Telehealth | FAIL | No certificate, lot report or test document appears on the product page, the terms, or among the 2,262 addresses the sitemap lists. |
| Modern Aminos | Research vendor | PASS | The certificate tab on the product page links a public file reporting 99.558 percent average purity by HPLC with mass spectrometry, reachable with no login. |
| Nextmeds | Telehealth | FAIL | Eight pages were read, covering home, about, contact, terms, privacy and the frequently asked questions, and none publishes a certificate of analysis, a lot number or a testing claim. |
| Nootropic Source | Research vendor | PASS | Three chromatograms are published as public product images, the newest dated 2019, reporting a 99.5343 percent assay on bromantane; neither GLP-1 product carries one. |
| Oak | Telehealth | FAIL | The product page publishes four named tests marked as passed, for potency within plus or minus 10 percent, sterility, pH and endotoxicity, and names no laboratory, no lot and no reachable document. |
| OrderlyMeds | Telehealth | FAIL | The site asserts batch testing for sterility and potency, and no certificate of analysis, chromatogram or lot document is reachable from any page read. |
| Peptide Pros | Research vendor | PASS | Twenty certificates are public files with no login, each naming the third-party laboratory MZ Biolabs of Tucson with a lot number, a date, a purity figure and the method; the BPC-157 certificate reports 100.0 percent on lot AF98762213. |
| Peptide Sciences | Research vendor | NOT VERIFIED | A purchasable storefront did not resolve, because the site announces a voluntary shutdown of operations. The check is open. |
| Pure Rawz | Research vendor | FAIL | The homepage asserts purity in marketing language, and no certificate, chromatogram or lot report was found on any captured page. |
| Remedy Meds | Telehealth | FAIL | The homepage prints four named tests marked passed, covering potency, sterility, pH and endotoxicity, and it names no laboratory, no lot and no document. |
| Ro | Telehealth | PASS | A sample certificate of analysis is published as a reachable image; the batch document for a buyer's own medication is available only inside the account. |
| Science.bio | Research vendor | NOT VERIFIED | A purchasable storefront did not resolve, because the whole domain now serves a single notice of permanent closure. The check is open. |
| Shed | Telehealth | FAIL | Ten pages were searched for thirteen certificate and testing terms, and none returns a certificate, a lot number or a purity figure. |
| Simple Peptide | Research vendor | PASS | A public certificate from Freedom Diagnostics gives 99.92 percent purity on semaglutide lot P24102404 by HPLC with mass spectrometry, reachable with no login. |
| SnagRx and Embody | Telehealth | FAIL | Updated reports on medication testing are described as received from pharmacies; no lot document is reachable on either storefront. |
| Sports Technology Labs | Research vendor | PASS | Certificates of analysis are published without a login, reporting 99.43 percent purity by HPLC-UV-MS from MZ Biolabs in Tucson. |
| Strut Health | Telehealth | FAIL | No certificate, lot report or test document appears on the product page, the FAQ, or in the published sitemap. |
| Swiss Chems | Research vendor | PASS | Third-party test reports published per product, principally from Janoshik Analytical. |
| Synergy Rx | Telehealth | FAIL | Four pages were read, covering home, the terms, about and contact, and none publishes a certificate, a lot number or any testing claim. |
| TrimRx | Telehealth | FAIL | No certificate of analysis, chromatogram or lot document is linked on any page read, and the safety page instead states that quality varies between compounding pharmacies. |
| Trinity Meds | Telehealth | FAIL | Eight pages were read, covering home, about, contact, terms, privacy and the frequently asked questions, and none publishes a certificate of analysis, a lot number or a testing claim. |
| Umbrella Labs | Research vendor | PASS | A public certificate from Vanguard Laboratory of Olympia reports chromatographic purity above 99.80 percent on semaglutide lot ULP-48813 by HPLC, reachable with no login. |
| Zealthy | Telehealth | FAIL | Twelve pages were searched for thirteen certificate and testing terms, and none returns a certificate, a lot number or a purity figure. |
Sources
Each source below is the analytical document a passing record cites, read on the date that record carries.
- Biotech Peptides, the document its S5 disposition cites
- Blue Sky Peptide, the document its S5 disposition cites
- Chemyo, the document its S5 disposition cites
- Core Peptides, the document its S5 disposition cites
- Limitless Life Nootropics, the document its S5 disposition cites
- Loti Labs, the document its S5 disposition cites
- Modern Aminos, the document its S5 disposition cites
- Nootropic Source, the document its S5 disposition cites
- Peptide Pros, the document its S5 disposition cites
- Ro, the document its S5 disposition cites
- Simple Peptide, the document its S5 disposition cites
- Sports Technology Labs, the document its S5 disposition cites
- Swiss Chems, the document its S5 disposition cites
- Umbrella Labs, the document its S5 disposition cites
Counts are computed from the ledger at build time against Standard v1.1, in the census run stated at the head of this page. Nulls are excluded from every numerator and named. A record filed under several storefronts is counted once.
Counts are generated from the ledger at build time, so this page cannot drift from the records it summarizes. Method and null semantics: how checks are performed. This page ranks nothing, recommends nothing, and carries no partner link.
Related findings
How many peptide sellers name the pharmacy that fills the order?A minority. Most sellers substitute a legal category, such as a licensed 503A pharmacy, for a facility a reader could look up in a state board register.
How many storefronts, and how many companies?Fewer companies than storefronts. Several records in the ledger are filed under more than one consumer domain, and one company names every website it operates in a single sentence of its own terms.
How many peptide sellers print a price before the intake form?A large majority. A price printed on a public page is the norm in this ledger, and the records that withhold one are named on the piece, with the withholding sentence quoted.
Where is the seller? Business address disclosure across the ledgerMost records print an address, and the addresses are not alike. Some are an office, some a registered agent's building, some a private mailbox, and a substantial minority print no address on any of the four surfaces read.
Warning letters across the field, and what happened nextA warning letter alleges and does not halt. The lettered entities in this ledger are counted with their denominator, together with how many still trade and how many letters carry a close-out letter on the FDA index.
The state of the Standard, edition 1Eight criteria applied to every record, each reported as its own pass, fail and not-verified count, split between telehealth services and research vendors. No criterion is summed with another, and no record is scored.
Which pharmacies fill the orders, and how many sellers name the same one?Fewer facilities than storefronts. Several sellers that look like separate businesses name the same filling pharmacy, and one facility appears in the ledger under several different spellings, each written by a different seller.
Where does the order path stop?Most stop, and the split is exact. Every record that puts an eligibility step in front of the order is a telehealth service, and every record that lets a product reach checkout unasked is a research vendor.
The question the regulator asked, and whether the record answers itSome answer it and some do not. The letters and the criterion ask the same question, and this piece reports only the dated state of both, because the ledger holds no earlier reading of those pages to compare against.